Publications by authors named "Mira Ali"
Background And Objective: Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis; however, teratogenicity was observed in animal studies. Given the potential for human fetal risk, pregnancy avoidance measures were required during clinical trials. This analysis describes pregnancy outcomes in patients exposed to upadacitinib during pregnancy.
View Article and Find Full Text PDFIntroduction: Data assessing longer-term real-world effectiveness and treatment patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid arthritis (RA) are lacking. We assessed improvement in clinical and patient-reported outcomes and treatment patterns for up to 12 months among adult patients with RA initiating UPA.
Methods: Data were collected from the CorEvitas RA Registry (08/2019-04/2022).
Introduction: The Routine Assessment of Patient Index Data 3 (RAPID3) is a patient-reported outcome tool recommended for the assessment of disease activity in patients with rheumatoid arthritis (RA) in clinical practice. This analysis evaluated the long-term effect of upadacitinib vs. comparators on RAPID3 scores in patients with RA in the phase 3 SELECT clinical trial program.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate how the sequence of treatments (upadacitinib vs adalimumab) affects patient outcomes after inadequate response to methotrexate.
- In a randomized trial, patients who did not show significant improvement were switched between therapies, and treatment effectiveness was measured over 48 weeks.
- Results indicated that while both treatments led to similar achievement rates of clinical targets, those starting with upadacitinib reached these targets quicker and experienced better overall effects.